BioPharma Today

Off-Label, Online: Know What The FDA Expects Before Internet Promotion Guidance Is Released

Add a new item to your web promotion compliance checklist: website color schemes. Seriously?  Click here for more information, or to register for this Aug. 10 webinar!

Clearly Understand Current & Potential Markets for Asia Pacific Healthcare Products

Arm Yourself to Implement Pragmatic Growth Strategies:

Complimentary Download: Exclusive Coverage on Avandia from "The Pink Sheet" DAILY

Perhaps the most anticipated FDA advisory committee meeting of 2010 has been the July 13-14 "rereview" of GlaxoSmithKline’s diabetes drug Avandia and particularly the drug's possible cardiovascular
risks.

"The Pink Sheet" DAILY set the stage with several in-depth articles exploring key issues leading up to the meeting and now is covering the committee's actions just as closely.

Get a free download of two of our most recent articles now, by going HERE.
"The Pink Sheet" DAILY will be providing continued Avandia coverage all week. Go to www.thepinksheetdaily.com to get a free trial subscription.

Register for the New York Pharma Forum

Register for the New York Pharma Forum Summer Social aboard the Intrepid with CEOs sharing their business wish lists ...

Merck: Poised to be THE biosimilars pioneer

Find out how they’ll do it and what it means for the rest of the industry in this FREE article just published in “The Pink Sheet” DAILY:
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.

DOWNLOAD FREE HERE: http://www.elsevierbi.com/mktg/HTML/pdwtl610.html

FT China Healthcare and Life Sciences Summit

As governments around the world grapple with the challenge of reforming their ailing healthcare systems, China has moved faster and further than most...

Finding the Future Value in Medicines - What Are The Most Promising Bets To Make?

It is clear that the pharmaceutical industry needs to evolve, but in which direction and how quickly? One thing is certain: Rewards will be great for companies that tap into new opportunities and align their business models and strategies for the future. In this complimentary webinar (Thursday, June 24), pharmaceutical industry strategist Robin Arnold, vice president of IMS Health’s Product and Portfolio Strategy practice, will reveal insights from the company’s recent global study of pharmaceutical market growth opportunities over the next decade. 

Win An Apple® iPad Just By Telling Us What You Think!

We need your input. How interested are you and your company in European biopharmaceutical news and analysis?

One From The Vaults: Our Interview With Mackay & Dolsten On Pfizer R&D

Today's story goes like this: AstraZeneca has snared Martin Mackay to head up its global R&D organization. Mackay, of course, previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.

He led half of Pfizer's R&D engine; the other half was led by Mikael Dolsten, who until today was head of Pfizer BioTherapeutics and Vaccines R&D. Before that Dolsten was head of Wyeth R&D - now he's head of Pfizer's worldwide R&D.

Following so far?

Is Teva's European Strategy A Threat To Brand Manufacturers?

Even as most of pharma sees Europe as a mature market ridden with pricing pressures, Teva, by far the world's largest and most successful generics manufacturer, is unabashedly targeting the region as an opportunity.